0001493152-26-009557
SEC filingBriaCell Therapeutics Corp. reported a net loss of $7.2 million attributable to the company for Q2 2026, with a net loss per share of $3.00. The company incurred total operating expenses of $7.5 million, primarily driven by research, development, and clinical trial expenses of $6.1 million. Cash flow from operations was negative $12.9 million, but the company significantly strengthened its liquidity position through financing activities, raising $27.9 million from share issuance and warrant exercises. This resulted in a $19.4 million increase in cash and cash equivalents, ending the period with $29.9 million in cash plus $7.4 million in short-term investments. Total assets stood at $33.6 million against total liabilities of $3.4 million, with shareholders' equity of $30.2 million. The company continues to be in a pre-revenue stage with no disclosed revenue figures for the period.
BriaCell Therapeutics Corp. reported a net loss of $7.2 million attributable to the company for the second quarter of fiscal year 2026, ending January 31, 2026. The company generated no revenue during the period, consistent with its clinical-stage biotechnology status. Total operating expenses were $7.5 million, consisting of $6.1 million in research, development, and clinical trial expenses and $1.5 million in general and administrative expenses. This resulted in an operating loss of $7.5 million. Additional losses included $85,000 in financial expenses, a $212,000 change in fair value of warrant liability, and $62,000 share of loss on equity investment. The net loss per share was $3.00 based on 2.8 million weighted average shares outstanding. No prior period comparisons are provided in the available data.
No revenue figures are disclosed in the provided financial data for BriaCell Therapeutics Corp. for Q2 2026. The company appears to be in a pre-revenue stage, which is typical for clinical-stage biotechnology companies focused on research and development. The financial statements show no revenue line items, and the income statement begins with operating expenses. All financial activity reflects the company's investment in research and development rather than commercial operations. No segment breakdown or geographic revenue mix is provided in the available data.
With no revenue generated during the period, traditional margin calculations (gross margin, operating margin) cannot be computed from the available data. The company reported an operating loss of $7.5 million, driven primarily by research and development expenses of $6.1 million (81% of total operating expenses) and general and administrative expenses of $1.5 million (19% of total operating expenses). The cost structure reflects the company's focus on clinical development activities rather than commercial operations. Share-based compensation of $286,000 was recorded as a non-cash expense during the period.
Cash flow from operating activities was negative $12.9 million, primarily due to the net loss of $7.3 million adjusted for non-cash items and changes in working capital, including a $1.4 million decrease in accounts payable. Cash flow from investing activities was positive $7.2 million, mainly from proceeds from short-term investments of $7.4 million, partially offset by a $165,000 equity investment in BC Therapeutics. Cash flow from financing activities was positive $27.9 million, consisting of $27.9 million from share issuance (net of costs) and $821,000 from warrant exercises. This resulted in a $19.4 million increase in cash and cash equivalents, ending at $29.9 million. Total assets were $33.6 million, including $7.4 million in short-term investments. Total liabilities were $3.4 million, with shareholders' equity of $30.2 million. The company's accumulated deficit stands at $127.2 million.
No specific management guidance, strategic priorities, or forward-looking statements are provided in the available financial data excerpts. The filing does not include risk factor disclosures or outlook commentary in the provided sections. The financial statements reflect the company's ongoing clinical-stage operations with significant investment in research and development. The substantial financing activities during the quarter ($27.9 million from share issuance) suggest continued funding of operations, but no explicit commentary on future plans or expectations is included in the provided data.